Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azimilide dihydrochloride.

Mark Carlson1

  • 1Case Western Reserve University, Department of Medicine, University Hospitals of Cleveland, Cleveland, OH 44106, USA. mark.carlson@case.edu

Expert Review of Cardiovascular Therapy
|May 14, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disinfection of poultry processing wastewater using advanced oxidation processes.

Poultry science·2026
Same author

Disinfection of Campylobacter Species and Salmonella Typhimurium in Contaminated Water Using Advanced Oxidation Processes.

Journal of food protection·2025
Same author

Impacts of almond pollination service and inter-row cover cropping on honey bee colony strength and performance.

The Science of the total environment·2025
Same author

Evaluation of the Use of Microtracers™ in a Proficiency Testing Program.

Journal of AOAC International·2019
Same author

Subclinical Atrial Fibrillation in Older Patients.

Circulation·2017
Same author

Response to letter regarding article "Temporal relationship between subclinical atrial fibrillation and embolic events".

Circulation·2015
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
Same journal

Contemporary approach and key considerations to asymptomatic aortic stenosis treatment.

Expert review of cardiovascular therapy·2026
Same journal

Giant cell myocarditis or sarcoidosis? Time to develop clinically driven non-invasive decision algorithms in inflammatory myocardial diseases: integrating clinical features, biomarkers and multimodality imaging.

Expert review of cardiovascular therapy·2026
See all related articles

Azimilide dihydrochloride is a Class III antiarrhythmic drug that blocks cardiac potassium channels, prolonging repolarization without rate-related effects. Clinical trials evaluated its use in treating supraventricular and ventricular arrhythmias.

Area of Science:

  • Pharmacology
  • Cardiology
  • Electrophysiology

Background:

  • Azimilide dihydrochloride is a novel antiarrhythmic agent.
  • It exhibits Vaughn Williams class III properties, targeting cardiac potassium channels.

Purpose of the Study:

  • To evaluate the efficacy and characteristics of azimilide dihydrochloride.
  • To assess its potential in treating supraventricular and ventricular arrhythmias.

Main Methods:

  • Pharmacological characterization of azimilide's interaction with cardiac potassium channels (IKr and IKs).
  • Assessment of its electrophysiological effects, including QT interval prolongation and lack of reverse-use dependence.
  • Pharmacokinetic analysis including bioavailability, peak concentration time, and elimination half-life.

Related Experiment Videos

  • Review of clinical trial data for supraventricular and ventricular arrhythmias.

    • Main Results:

    • Azimilide blocks both IKr and IKs potassium channels.
    • It slightly slows heart rate and prolongs the QT interval.
    • Unlike sotalol, azimilide does not show reverse-use dependence.
    • The drug has 85% bioavailability, a long half-life (114 h), and is suitable for once-daily dosing.

    Conclusions:

    • Azimilide is a Class III antiarrhythmic with unique properties, including lack of reverse-use dependence.
    • Its favorable pharmacokinetic profile supports once-daily dosing.
    • Clinical trials indicate its potential for managing supraventricular and ventricular arrhythmias.